Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Mar;56(3):1627-9.
doi: 10.1128/AAC.05739-11. Epub 2011 Dec 19.

Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir

Ivy Song  1 , Julie Borland, Shuguang Chen, Parul Patel, Toshihiro Wajima, Amanda Peppercorn, Stephen C Piscitelli
Affiliations
Randomized Controlled Trial

Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir

Ivy Song et al. Antimicrob Agents Chemother. 2012 Mar.

Abstract

Healthy subjects received dolutegravir at 50 mg in a single-dose crossover study while they were in the fasted state or with low-, moderate-, or high-fat meals. Food increased dolutegravir exposure and reduced the rate of absorption. The area under the concentration-time curve from 0 h to infinity (AUC(0-∞)) increased by 33%, 41%, and 66% when administered with low-, moderate-, or high-fat meals, respectively, compared with fasting. This increase in dolutegravir exposure is not anticipated to impact clinical safety, and therefore dolutegravir can be taken with or without food and without regard to fat content.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Mean concentration-time profiles of DTG administered in the fasting state or with meals with various fat contents.
See this image and copyright information in PMC

References

    1. Brainard DM, et al. 2011. Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics. J. Clin. Pharmacol. 51:422–477 - PubMed
    1. Bristol-Myers Squibb 2011. Atripla (package insert). Bristol-Myers Squibb and Gilead Sciences, New York, NY
    1. Kobayashi M, et al. 2011. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob. Agents Chemother. 55:813–821 - PMC - PubMed
    1. Lenz JC, Rockstroh JK. 2011. S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges. Expert Opin. Invest. Drugs 20:537–548 - PubMed
    1. Min S, et al. 2010. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob. Agents Chemother. 54:254–258 - PMC - PubMed

Publication types

MeSH terms